EF-32 (TRIDENT): A Pivotal Randomized, Open-Label Study Of Optune® (Ttfields, 200khz) Concomitant With Radiation Therapy And Temozolomide For The Treatment Of Actively Diagnosed Glioblastoma Read more
A Phase I Study to Evaluate the Pharmacokinetics and Safety of belantamab mafodotin Monotherapy in Participants with Relapsed and/or Refractory Multiple Myeloma (RRMM) Who Have Normal and Varying Degrees of Impaired Renal Function (DREAMM 12) Read more
A Phase I Study to Evaluate the pharmacokinetics and safety of Belantamab Mafodotin Monotherapy in participants with Relapsed or Refractory Multiple Myeloma who have normal and varying degrees of impaired hepatic function (DREAMM 13) Read more
An Open-Label, Multicenter, Non-Randomized Phase 2 Study Of Pf-06863135 Monotherapy In Participants With Multiple Myeloma Who Are Refractory To At Least One Proteasome Inhibitor, One Immunomodulatory Drug And One Anti-Cd38 Antibody Read more
A Phase I In Human Study Evaluating The Safety, Tolerability, Pharmacokinetics And Pharmacodynamics Of AMG 176 In Subjects With Relapsed Or Refractory Multiple Myeloma Read more
A Single-Arm, Open-Label, Phase 1 Study Of The Safety, Efficacy, And Cellular Kinetics/Pharmacodynamics Of ALLO-715 To Evaluate An Anti-BCMA Allogeneic CAR T Cell Therapy In Subjects With Relapsed/Refractory Multiple Myeloma Read more
A Phase 2, Multi-Cohort, Open-Label, Multicenter Study To Determine The Efficacy And Safety Of BB2121 In Subjects With Multiple Myeloma (Karmma-2) Read more
A Phase 3, Multicenter, Randomized, Open Label Study To Compare The Efficacy And Safety Of Bb2121 Versus Standard Triplet Regimens In Subjects With Relapsed And Refractory Multiple Myeloma Read more
A Phase 1, Open-Label, Multicenter Study To Evaluate The Safety Of Bb2121 In Subjects With High Risk, Actively Diagnosed Multiple Myeloma (Karmma-4) Read more
